Details

Autor(en) / Beteiligte

• Wang, Min-min
• Chen, Shi-jun
• Ye, Qi-fa
• Yang, Yi-jun
• Chen, Shi-bin
• Zhou, Xin-min
• Guo, Li-min
• Zhang, Yue-xin
• Ding, Xiao-qiang
• Hu, Xiao-bin
• Luo, Hong-tao
• Liu, Yi-he
• Wang, Wen-ya

Titel

Liver support therapy with molecular adsorbents recirculating system in liver failure： a summary of 252 cases from 14 centers in China

Ist Teil von

• Chinese medical journal, 2008-11, Vol.121 (21), p.2197-2201

Ort / Verlag

China: Therapeutic Blood Purification Research Center,University of Rostock,Germany%Department of Artificial Liver Therapy,Jinan Infectious Diseases Hospital,Jinan,Shandong 250021,China%Xiangya Transplantation Medical Academy,Central South University,Changsha,Hunan 410013,China%Department of Artificial Liver Therapy,Nanjing Second People's Hospital,Southeast University Medical College,Nanjing,Jiangsu 210003,China%Division of Infectious Diseases,First Affiliated Hospital of Jiangxi Medical College,Nanchang,Jiangxi 330006,China%Institute of Digestive Diseases,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 400038,China%ICU & Artificial Liver Support Center,Beijing Ditan Hospital,Beijing 100011,China%Institute of Hepatology,First Hospital,Xinjiang Medical University,Urmqi,Xinjiang 830000,China%Department of Nephrology,Fudan University Zhongshan Hospital,Shanghai 200032,China%Department of Artificial Liver Therapy,Guangzhou No.8Hospital,Guangzhou,Guangdong 510060,China%ITU & Blood Purification Center,First People's Hospital of Foshan,Foshan,Guangdong 528000,China%Tianjin First Central Hospital,Tianjin Organ Transplantation Institute,Tianjing 300192,China%Department of Infectious Diseases,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Background A liver support therapy, named molecular adsorbents recirculating system （MARS）, has been used for more than 700 liver failure patients in China. We made here a summary to evaluate the effects of MARS treatment in different applications with emphasis on hepatitis B virus （HBV） based liver failure. Methods This report analyzed data of 252 patients （mean age （44.9±12.7） years） in three groups： acute severe hepatitis （ASH）, subacute severe hepatitis （SSH） and chronic severe hepatitis （CSH）. The largest group was CSH （156 patients, 61.9%）, and 188 patients （74.6%, 188/252） were infected with HBV. Results MARS treatments were associated with significant reduction of albumin bound toxins and water-soluble toxins. Most of the patients showed a positive response with a significant improvement of multiple organ function substantiated by a significant increase in prothrombin time activity （PTA） and median arterial pressure （MAP）. There was a decrease in hepatic encephalopathy （HE） grade and Child-Turcotte-Pugh （CTP） scale. Thirty-nine of 188 HBV patients （20.7%） dropped out of the commendatory consecutive therapy ending with lower survival of 43.6% while the rest of the 149 patients had a survival rate of 62.4%. Survival within the ASH and SSH groups were 81.2% and 75.0%, respectively. In the CSH group, end stage patients were predominant （65/151,43%）, whereas the early and middle stage patients had a better prognosis： early stage survival, including orthotopic liver transplantation （OLT） survival of 91.7%, middle stage survival of 75%, end stage survival of 33.8%. Conclusions MARS continues to be the most favorable extracorporeal treatment for liver support therapy in China for a wide range of conditions, including the majority of hepatitis B related liver failure conditions. The appropriate application of MARS for the right indications and stage of hepatic failure, as well as the fulfillment of prescribed treatments, will lead to the optimal therapeutic result.